Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action. by Fujita, Yoshihito & Inagaki, Nobuya
Title
Renal sodium glucose cotransporter 2 inhibitors as a novel
therapeutic approach to treatment of type 2 diabetes: Clinical
data and mechanism of action.
Author(s)Fujita, Yoshihito; Inagaki, Nobuya




© 2014 The Authors. Journal of Diabetes Investigation
published by Asian Association of the Study of Diabetes
(AASD) and Wiley Publishing Asia Pty Ltd.; This is an open
access article under the terms of the Creative Commons
Attribution-NonCommercial License, which permits use,
distribution and reproduction in any medium, provided the





Renal sodium glucose cotransporter 2
inhibitors as a novel therapeutic approach to
treatment of type 2 diabetes: Clinical data and
mechanism of action
Yoshihito Fujita, Nobuya Inagaki*
Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Keywords
Novel antidiabetic agents, Renal








J Diabetes Invest 2014; 5: 265–275
doi: 10.1111/jdi.12214
ABSTRACT
Type 2 diabetes is characterized by impaired insulin secretion from pancreatic b-cells and/
or reduced response of target tissues to insulin. Good glycemic control delays the devel-
opment and slows the progression of micro- and macrovascular complications. Although
there are numerous glucose-lowering agents in clinical use, only approximately half of
type 2 diabetic patients achieve glycemic control, and undesirable side-effects often ham-
per treatment in those treated with the medications. There is a need for novel treatment
options that can help overcome these difficulties. Sodium glucose cotransporter 2 (SGLT2)
inhibitors have recently been developed as a novel potential therapeutic option for the
treatment of type 2 diabetes. These drugs lower the plasma glucose concentration
through inhibition of glucose reuptake in the kidney, independent of insulin secretion and
insulin action, with a consequent lower risk of hypoglycemia. The data of clinical trials
with monotherapy as well as combination therapy show that SGLT2 inhibitors have a
blood glucose-lowering effect and also reduce bodyweight. A follow-up study shows
long-term efficacy and the durability of these effects. SGLT2 inhibitors have the potential
to reverse glucose toxicity, and to improve insulin resistance, blood pressure and lipid
profile. The available data suggest a good tolerability profile. However, clinicians should
carefully prescribe these drugs in light of already reported and/or unexpected side-effects.
Further studies in larger numbers and longer-term clinical use data are required to place
these agents in standard treatment of type 2 diabetes.
INTRODUCTION
The increasing prevalence of diabetes now afflicts 382 million
people worldwide, and this number is expected to rise to
592 million by 2,0351. The great majority (approximately 90%)
of diabetes is type 2 diabetes2. Type 2 diabetes is characterized
by impaired insulin secretion from pancreatic b-cells and/or
reduced response of target tissues to insulin (insulin resis-
tance)3,4. Chronic hyperglycemia is associated with development
of micro- and macrovascular complications, which contribute
to mortality and morbidity5,6. Good glycemic control is desired
to prevent the development and slow the progression of these
complications7–10.
At present, there are numerous oral and injectable agents in
clinical use11. Oral antihyperglycemic agents include biguanides,
sulfonylureas, a-glucosidase inhibitors, dipeptidyl peptidase-4
(DPP4) inhibitors, meglitinides and thiazolidinediones. Inject-
able antihyperglycemic agents include incretin-related agents,
such as liraglitide and exenatide, and various insulins. Most of
these agents are initially effective, but fail in the long term to
maintain normoglycemia as monotherapy, resulting in a
requirement for multiple antihyperglycemic therapies12. Despite
the variety of treatment options, just half of type 2 diabetes
patients achieve glycemic control with hemoglobin A1c lower
than 7.0%13. In addition, undesirable side-effects often hamperReceived 30 January 2014; accepted 31 January 2014
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treatment with these medications. For example, insulin and
insulin secretagogues, such as sulfonylureas, are associated with
hypoglycemia and weight gain, thiazolidinediones are associated
with weight gain and edema, metformin can cause gastrointesti-
nal effects, and rarely, lactic acidosis. Hence, there is a need for
novel treatment options that that can help overcome these diffi-
culties.
Inhibitors of sodium glucose cotransporter 2 (SGLT2) have
recently been developed as a novel potential therapeutic option
for the treatment of type 2 diabetes14,15. SGLT2 inhibitors lower
the plasma glucose concentration by inhibition of glucose reup-
take in the kidney, without weight gain. As the mechanism of
action of SGLT2 inhibitors is independent of insulin secretion
and insulin action, they lower the plasma glucose concentration
with lower risk of hypoglycemia. In the present article, we
review the role of SGLT2 in glucose homeostasis, the develop-
ment of SGLT2 inhibitors, findings from clinical trials of
SGLT2 inhibitors, and the potentials and safety concerns in the
treatment of type 2 diabetes.
ROLE OF THE KIDNEY IN GLUCOSE HOMEOSTASIS
The kidneys play an important role in glucose homeostasis, pri-
marily through reabsorption of filtered glucose, glucose produc-
tion (gluconeogenesis likely in the liver) and consumption16.
The kidneys normally filter approximately 180 g of serum glu-
cose in the glomeruli, which is then reabsorbed completely in
the proximal tubules; urine is thus normally negative for glu-
cose15,17. However, as plasma glucose concentrations approach
approximately 180 mg/dL and cross over a threshold, glucose
appears in the urine18. Glucose reabsorption at the renal tubules
is mediated by two groups of transporters. These include glu-
cose transporters (GLUTs) and sodium-glucose cotransporters
(SGLTs; Figure 1). GLUTs are facilitative or passive transport-
ers that transport glucose along the concentration gradient.
SGLTs are a large family of membrane proteins that transport
glucose across the brush border membrane of the intestinal epi-
thelium and proximal renal tubules using the electro-chemical
sodium gradient as the source of energy generated by Na+/K+
adenosine triphosphatase16,19–21. SGLT1 is a high-affinity, low-
capacity transporter and is expressed mainly in the small intes-
tine, where it plays a role in the absorption of glucose and
galactose, as well as in the proximal tubules in the kidney.
SGLT2 is a low-affinity, high-capacity transporter and is
expressed particularly in proximal tubules in the kidney14,22,23.
The proximal tubules in the kidney are divided to three seg-
ments (S1, S2 and S3) anatomically. SGLT2 is located in S1
and accounts for 90% of the glucose reabsorbed from the kid-
neys; SGLT1 is located in S2 and S3, and accounts for the
remaining 10% (Figure 1).
People with genetically inherited SGLT1 mutations show
malabsorption, severe osmotic diarrhea and dehydration24. In


































Figure 1 | Renal glucose handling in a non-diabetic individual. (a) Glucose reabsorption in the kidney. (b) Glucose reabsorption through sodium
glucose cotransporter (SGLT)1 and SGLT2 in the proximal renal tubular cell. ADP, adenosine diphosphate; ATP, adenosine triphosphate; GLUT,
glucose transporter; S1, segment1; S2, segment 2; S3, segment 3.
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have familial renal glucosuria, but most cases are otherwise nor-
mal and healthy25,26. Interestingly, these people do not exhibit
show regardless of virtually absent glucose reabsorption. In
addition, it is reported that in individuals with type 2 diabetes,
there is evidence that renal glucose reabsorption might be
enhanced14,18. Therefore, even in the presence of hyperglycemia,
the kidneys continue to reabsorb glucose, with the net effect of
further promotion of hyperglycemia. These observations show
that inhibition of SGLT2 might be a reasonable approach to
the control of blood glucose levels in type 2 diabetes, and have
led to the development of the SGLT2 inhibitors. Inhibition of
glucose uptake by the kidneys appears to be a novel, unique
and promising insulin-independent approach to the treatment
of type 2 diabetes.
DEVELOPMENT OF SGLT2 INHIBITORS
Interest in SGLT2 inhibitors originated with the demonstration
that phlorizin, originally isolated from the bark of apple trees
in 1,835, in France27, non selectively inhibits SGLT1 and
SGLT2, normalizes plasma glucose concentrations, and reverses
insulin resistance in animal models of diabetes28. Phlorizin
induces glucosuria by inhibiting SGLT in the kidneys27, and
reduces serum glucose in diabetic animal models. Furthermore,
phlorizin improves insulin resistance and b-cell dysfunction by
mitigating “glucose toxicity”, a deteriorating cycle in diabetes in
which hyperglycemia itself can further compound the levels of
insulin resistance and insulin deficiency. However, clinical
development of phlorizin was stopped because of its poor
absorption after oral administration and severe gastrointestinal
side-effects, such as diarrhea, induced by SGLT1 inhibition.
Efforts were made to develop new compounds to inhibit
SGLT2 with high potency and selectivity. To overcome the limi-
tations of phlorizin, a number of oral SGLT2 inhibitors, all
derived from the basic structure of phlorizin, have been synthe-
sized and are in clinical development for the treatment of type 2
diabetes (Table 1). These SGLT2 inhibitors have high potency
and high selectivity against SGLT2 over SGLT1 (Table 2). Dapa-
gliflozin was approved in Europe in 2012 and in the USA in
201429, canagliflozin was approved in the USA in 2013, ipragli-
frozin has been approved in Japan in 2014, and these or several
other SGLT2 inhibitors will soon be approved in Europe, the
USA and other countries, such as Japan.
In contrast, it has been reported that SGLT1-deficient mice
lose just ~3% of the filtered glucose into the urine, whereas
SGLT2-deficient mice lose ~60% of the filtered glucose into the
urine, suggesting that wild-type mice do not use the maximal
transport capacity of SGLT1 under normoglycemic condi-
tions30. In diabetic patients, the glucose concentration is over-
whelming in early proximal tubules, and even more so in
patients with an SGLT2-specific inhibitor. In this condition, an
SGLT1 transporter might be performing at full capacity, and
therefore minimize the effects of the drug31,32. In this context,
SGLT1 inhibition might have therapeutic potential. One mixed
SGLT1 and SGLT2 inhibitor (LX-4211) has been identified,
and is currently in development33.
We next review the six representative types of SGLT2 inhibi-
tor that offer the best available evidence in humans: dapagliflo-
zin, canagliflozin, empagliflozin, ipragliflozin, luseogliflozin and
tofogliflozin.
CLINICAL TRIALS OF SGLT2 INHIBITORS
The data of clinical trials of these six agents with monotherapy
for 16–24 weeks are shown in Table 3 and Figure 2. All types
of SGLT2 inhibitors have a glucose-lowering effect with mono-
therapy, and have an additional effect in reducing bodyweight.
They lower the glycated hemoglobin (HbA1c) level by
0.58–1.03% from baseline. They are associated with clinically
significant weight reductions by 2.2–3.4 kg, which have been
attributed to glycosuria, with a loss of approximately 200–
300 Kcal per day. Although several glucose-lowering drugs
exert a different effect in Caucasians and Asians because of dif-
ferences of insulin secretory capacity and/or insulin sensitivity,
Table 1 | List of sodium glucose cotransporter 2 inhibitors under
clinical development
Drug Company Clinical stage
Canagliflozin Mitsubishi Tanabe,
Janssen








Filed in USA, EU and Japan
Ipragliflozin Astellas, Kotobuki Approved in Japan
Luseogliflozin Taisho Filed in Japan
Tofogliflozin Chugai, Kowa, Sanofi Filed in Japan
Ertugliflozin Merck, Pfizer Phase III in USA,phase I in
Japan
LX-4211 Lexicon Phase II in USA
EU, Europe.
Table 2 | In vitro inhibitory concentration 50 values against human
sodium glucose cotransporter 2 and sodium glucose cotransporter 1,
and sodium glucose cotransporter 2 selectivity67,73,77–81






Canagliflozin 4.4 684 155
Dapagliflozin 1.12 1,391 1,242
Empagliflozin 3.1 8,300 2,680
Ipragliflozin 7.38 1,876 254
Luseogliflozin 2.26 3,990 1,770
Tofogliflozin 2.9 8,444 2,912
Phrorizin 34.6 210 6
Sodium glucose cotransporter (SGLT)2 selectivity was calculated by
using the following formula: inhibitory concentration 50 (IC50) value for
SGLT1/IC50 value for SGLT2.
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the favorable effects of SGLT2 inhibitors are obtained to the
same extent regardless of difference of race34,35. The reason
might be derived from the unique mechanism of action of
SGLT2 inhibitors, which act independently of insulin secretion
and insulin sensitivity. Furthermore, because of this unique
mechanism of action, SGLT2 inhibitors are effective in lowering
HbA1c at all stages of diabetes, and can be used in combina-
tion with other glucose-lowering agents including insulin36,37.
In follow-up clinical trials, the long-term efficacy of SGLT2
inhibitors and their efficacy in combination therapy with other
glucose-lowering therapies became available.
Canagliflozin
Canagliflozin is the first SGLT2 inhibitor approved by the US
Food and Drug Administration (FDA), and was available on
the market in 201338. At week 26 of monotherapy, canagliflozin
100 mg and 300 mg reduced HbA1c vs placebo (-0.77, -1.03,
+0.14%, respectively; P < 0.001)39. At week 52, canagliflozin
100 mg and 300 mg showed non-inferiority, and canagliflozin
300 mg showed statistical superiority to sitagliptin in lowering
HbA1c (-0.73, -0.88, -0.73%, respectively)40. Canagliflozin 100
and 300 mg reduced bodyweight vs placebo (week 26: -3.7,
-4.2, -1.2%, respectively; P < 0.001) and sitagliptin (week 52:
-3.8, -4.2, -1.3%, respectively; P < 0.001). Both canagliflozin
doses reduced fasting blood glucose and systolic blood pressure
vs placebo (week 26) and vs sitagliptin (week 52; P < 0.001).
In the combination therapy, canagliflozin also improved glyce-
mic control, reduced bodyweight and was generally well toler-
ated in type 2 diabetes patients on metformin plus
sulphonylurea over 52 weeks41. HbA1c was significantly
reduced with canagliflozin 100 and 300 mg vs placebo at
week 26 (-0.85, -1.06, -0.13%; P < 0.001); these reductions
were maintained at week 52 (-0.74, -0.96, 0.01%). Reductions
in HbA1c with canagliflozin 100 mg (-0.82%) and 300 mg/day
(-0.93%) were non-inferior to those with glimepiride (titration
of glimepiride ranged from a starting dose of 1 mg to a maxi-
mum dose of 6 or 8 mg; -0.81%) over the course of 52 weeks
of treatment in patients on background metformin. Canagliflo-
zin 300 mg/day was superior to glimepiride in reducing
HbA1c, and both doses of canagliflozin were superior to glim-
epiride in reducing bodyweight (-3.7 kg with 100 mg/day,
-4.0 kg with 300 mg/day vs +0.7 kg with glimepiride41. In the
body composition substudy, patients had baseline characteristics
and weight changes over 52 weeks that were generally similar
to those reported in the main study. In the canagliflozin
groups, roughly two-thirds of the reduction in bodyweight was
from fat mass, and one-third was from lean body mass; the
increase in bodyweight with glimepiride included both fat and
lean body mass. Analysis of abdominal fat in the canagliflozin
groups with computed tomography imaging showed a slightly
greater reduction in visceral adipose tissue than that in subcuta-
neous adipose tissue. In the follow-up study of the aforemen-
tioned study up to 2 years, HbA1c reductions were maintained
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Figure 2 | Results of trials with sodium glucose cotransporter 2 inhibitors. Changes in (a) glycated hemoglobin (HbA1c), (b) fasting plasma glucose
and (c) bodyweight39,55,82–85. PBO, placebo.
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at week 104 (-0.65, -0.746 and -0.55%), and both doses of
canagliflozin were superior to glimepiride in reducing body-
weight (-4.1% with 100 mg/day, -4.2% with 300 mg/day vs
+0.9% with glimepiride; Table 4)42.
Dapagliflozin
Dapagliflozin was the first approved SGLT2 inhibitor, and
there is much published clinical trial data. In 24-week,
placebo-controlled, phase 3 trials, dapagliflozin (2.5, 5 and
10 mg once daily) used as monotherapy or as add-on therapy
to metformin43, glimepiride44, pioglitazone45 or insulin46
reduced HbA1c and fasting plasma glucose in patients with
type 2 diabetes. A long-term follow-up trial also showed bene-
ficial effects of dapagliflozin. Dapagliflozin added to metformin
for 102 weeks resulted in sustained reductions in HbA1c, fast-
ing blood glucose and weight without increased risk of hypo-
glycemia in patients with type 2 diabetes inadequately
controlled by metformin alone47. At week 102, mean changes
from baseline HbA1c (8.06%) were +0.02% for placebo com-
pared with -0.48% (P = 0.0008), -0.58% (P < 0.0001) and
-0.78% (P < 0.0001) for dapagliflozin 2.5–5 and 10 mg,
respectively. In addition, all dapagliflozin groups had sustained
reductions from baseline in fasting plasma glucose and body-
weight at 102 weeks, whereas increases were noted in placebo-
treated patients for both of these outcomes. Dapagliflozin was
also compared with glipizide in patients whose hyperglycaemia
was inadequately controlled by metformin48. After 1 year, a
similar HbA1c reduction from baseline of -0.52% was seen
with dapagliflozin (≤10 mg/day) and glipizide (≤20 mg/day). A
decrease from baseline in bodyweight of -3.2 kg occurred with
dapagliflozin, compared with a weight gain of 1.4 kg with gli-
pizide. Dapagliflozin has the longest term follow-up results
among SGLT2 inhibitors. In a randomized, double-blind trial
of dapagliflozin (≤10 mg/day) vs glipizide (≤20 mg/day) as
add-on to metformin in type 2 diabetes, dapagliflozin was
non-inferior to glipizide in HbA1c change at 52 weeks (both
-0.52%), and produced weight loss. The 4-year data showed
that the effect of therapy on HbA1c was attenuated over time
in both groups, but dapagliflozin showed more persistent
benefits vs glipizide (change from baseline of -0.1 vs +0.2%):
treatment difference -0.30% (95% confidence interval (CI)
-0.51 to -0.09; Table 4)49. Sustained and stable weight loss
was observed with dapagliflozin vs weight gain with glipizide
(-3.95 vs +1.12 kg): treatment difference -5.07 kg (95% CI
-6.21 to -3.93). Mean systolic blood pressure was reduced
with dapagliflozin, but not with glipizide (difference:
-3.7 mmHg, 95% CI -5.9 to -1.4).
Empagliflozin
Empagliflozin (5–25 mg/day for 12 weeks) increased glucose
excretion, and decreased fasting plasma glucose (-31.1 mg/dL
at 25 mg vs an increase of 0.8 mg/dL with placebo), HbA1c
(-0.63% at 25 mg vs an increase of 0.09%) and bodyweight
(-2.0 kg at 2 mg vs -0.8 kg) in patients with type 2 diabetes50.
In a randomized to double-blind empagliflozin (10, 25 mg) or
placebo add-on to basal insulin for 78 weeks, empagliflozin sig-
nificantly reduced HbA1c (empagliflozin 10 mg: -0.48%,empa-
gliflozin 25 mg: -0.64%,placebo: -0.02%), bodyweight
(empagliflozin 10 mg: -2.2 kg,empagliflozin 25 mg: -2.0 kg,
placebo: +0.7 kg; Table 4). Furthermore, empagliflozin 10 mg
significantly reduced systolic blood pressure (empagliflozin
4 mg: -4.1 mmHg, empagliflozin 25 mg: -2.4 mmHg,placebo:
+0.1 mmHg)51. In a randomized, open-label, 78-week blinded
study of empagliflozin (monotherapy at doses of 10 mg or
25 mg, and add-on to metformin) with metformin, and sitag-
liptin as add-on to metformin, changes from baseline in HbA1c
at week 90 were -0.34 to -0.63% with empagliflozin, -0.56%
with metformin, and -0.40% with sitagliptin. Changes in weight
from baseline at week 90 were -2.2 to -4.0 kg with empagliflo-
zin, -1.3 kg with metformin and -0.4 kg with sitagliptin52.
Thus, long-term empagliflozin treatment can provide sustained
glycemic and weight control in patients with type 2 diabetes.
Ipragliflozin
In a 24-week trial in patients with type 2 diabetes inadequately
controlled with metformin alone, ipragliflozin (50 mg/day)
decreased HbA1c by -0.87% vs an increase of 0.38% with pla-
cebo (P < 0.001). Bodyweight was also reduced with ipragliflo-
zin (-2.3 kg vs -0.6 kg)53. The beneficial effects of ipragliflozin
(50–100 mg/day) on HbA1c (-0.51%) and bodyweight
Table 4 | Clinical data of long-term efficacy using sodium glucose cotransporter 2 inhibitors
Canagliflozin Dapagliflozin Empagliflozin
Combination with metformin Combination with
metformin
Combination with insulin
104 weeks 4 years 78 weeks
SU 100 mg 300 mg SU Dapagliflozin PBO 10 mg 25 mg
HbA1c change (%) -0.55 -0.65 -0.74 0.2 -0.1 -0.02 -0.48 -0.64
Bodyweight change (kg) – – – 1.12 -3.95 0.7 -2.2 -2
Bodyweight change (%) 0.9 -4.1 -4.2 – – – – –
HbA1c, glycated hemoglobin; PBO; placebo, SU; sulfonylurea.
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(-3.41 kg) were sustained for up to 52 weeks in Japanese
patients with type 2 diabetes54.
Luseogliflozin
Clinical trials of luseogliflozin as monotherapy or add-on
therapy to five types of oral antidiabetic drugs for 52 weeks in
Japanese patients with type 2 diabetes mellitus showed that
luseogliflozin improves glycemic control and reduces body-
weight. Changes in HbA1c after 52 weeks were monotherapy:
-0.50%,add-on to glimepiride: -0.63%,add-on to metformin:
-0.61%,add-on to DPP4 inhibitors: -0.52%,add-on to pioglitaz-
one: -0.60%,add-on to glinide: -0.59%,and add-on to a-glucosi-
dase inhibitor: -0.68%.Changes in bodyweight after 52 weeks
were monotherapy: -2.7 kg,add-on to glimepiride: -2.2 kg,add-
on to metformin: -2.9 kg,add-on to DPP4 inhibitors: -2.0 kg,
add-on to pioglitazone: -2.3 kg,add-on to glinide: -2.9 kg and
add-on to a-glucosidase inhibitor: -2.8 kg.Furthermore, luseo-
gliflozin decreased blood pressure and showed trends toward
improvement in plasma lipids (triglyceride and high-density
lipoprotein (HDL) cholesterol) at week 52 compared with base-
line55–57.
Tofogliflozin
Clinical trials of tofogliflozin as monotherapy or add-on ther-
apy to oral antidiabetic drugs for 52 weeks in Japanese patients
with type 2 diabetes mellitus showed that tofogliflozin
improved glycemic control and reduced bodyweight. With
monotherapy, change in HbA1c from baseline was -0.7% (both
20 and 40 mg), and change in bodyweight was –3.1 kg
(20 mg) and –3.4 kg (40 mg). With combination therapy,
change in HbA1c from baseline was –0.8% (20 mg) and –0.9%
(40 mg), and change in bodyweight was -2.5 kg (20 mg) and
-3.0 kg (40 mg). Furthermore, reduced systolic and diastolic
blood pressure, improved homeostasis model assessment of
insulin resistance, increased serum adiponectin and HDL cho-
lesterol levels were secondarily observed58.
SAFETY OF SGLT2 INHIBITORS
Urinary Tract and Genital Infections
One of the major safety concerns of SGLT2 inhibition is that
by their very nature, the drugs cause glucose elevation in the
urine that can lead to urinary tract and genital infections,
electrolyte imbalances, and increased urinary frequency. For
example, frequency in urinary infections and genital infections
reported in clinical trials were 2.8% (dapaglifrogin 5 mg),
7.2% (canagliflozin 100 mg)39,44. In the meta-analysis, urinary
tract infections were more common among patients treated
with SGLT2 inhibitors than among those receiving placebo
(odds ratio [OR] 1.34, 95% CI 1.03–1.74]; I2 = 0%)59. We also
found an increased incidence of genital tract infections with
SGLT2 inhibitors compared with placebo (OR 3.50, 95% CI
2.46–4.99; I2 = 0%) and active comparators (OR 5.06, 95% CI
3.44–7.45; I2 = 0%). Females were more prone to infection
than males.
Hypoglycemia
Because their mechanism of action is not dependent on insulin
secretion, SGLT2 inhibitors are less likely to cause hypoglyce-
mia, an adverse effect of some antihyperglycemics60. The inci-
dence of hypoglycemia was low in most treatment groups,
except among patients receiving a sulfonylurea or insulin as
allocated treatment or background therapy59,60.
Cancer Risk
An increased incidence of bladder and breast cancer was identi-
fied in the dapagliflozin trials. Among 5,478 patients who
received dapagliflozin, there were nine cases of bladder cancer
compared with one case in 3,136 patient controls60,61. There
were nine cases of breast cancer in 2,223 patients receiving
dapagliflozin therapy compared with one case in 1,053 con-
trols61. In 2011, a FDA Advisory Committee voted against
approval of dapagliflozin because of concerns about increased
risk for bladder and breast cancer61,62, and the FDA requested
additional clinical trial data to determine the risk-to-benefit
ratio of this therapy. Further data analysis has been ongoing to
determine the potential increased risk of cancer with dapagliflo-
zin therapy. In January 2014, the FDA approved dapaglifozin
to improve glycemic control, along with diet and exercise, in
adults with type 2 diabetes29. A pooled analysis of nine trials
with approximately 8,000 person-years of exposure did not
show any difference in incidence of bladder cancer between
canagliflozin (5 of 6,648 patients) and control (4 of 3,640
patients) groups59. Similarly, the incidence of breast cancer did
not differ between canagliflozin (12 of 2,827 patients) and com-
parators (6 of 1,501 patients). However, clinicians must be cau-
tious of the incidence of cancer risk in long-term clinical use of
SGLT2 inhibitors, and long-term follow-up data and cumulative
data on the association of cancer incidence and SGLT2 inhibi-
tors are required.
Cardiovascular Outcomes
The meta-analysis of cardiovascular outcomes for dapagliflozin,
which was based on 14 trials (n = 6,300), yielded an OR of
0.73 (95% CI 0.46–1.16; I2 = 0%) compared with control59. In
a pooled analysis of two dapagliflozin trials in patients with
established cardiovascular disease63,64, the hazard ratio for the
composite cardiovascular end-point (cardiovascular death,
myocardial infarction, stroke and hospitalization for unstable
angina) was 1.07 (95% CI 0.64–1.72) vs placebo65. Canagliflo-
zin was not associated with an increased risk for the compos-
ite cardiovascular outcome compared with placebo or active
comparator on the basis of data from 10 trials that included a
total of 10,474 patients. In the FDA report66, the HR for non-
fatal stroke was higher in patients receiving canagliflozin
(6,876 patient-years) than in the control groups (3,470 patient-
years; HR 1.46, 95% CI 0.83–2.58). In addition, an imbalance
in the incidence of cardiovascular events observed during the
first 30 days of the dedicated cardiovascular trial66 between
canagliflozin (13/2,886 patients) and a placebo (1/1,441
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patients) resulted in a HR of 6.50 (95% CI 0.85–49.66), possi-
bly as a result of volume depletion after canagliflozin initia-
tion. This imbalance was not evident after 30 days. Data on
cardiovascular outcomes and death were inconclusive. The
numerical imbalance in non-fatal stroke events among patients
treated with canagliflozin requires clarification and confirma-
tion. Follow-up trials of cardiovascular outcomes in clinical
use of several SGLT2 inhibitors including a canagliflozin are
ongoing60.
Others
A higher risk of hypotension with SGLT2 inhibitors was
induced than with other antidiabetic medications (OR 2.68,
95% CI 1.14–6.29)59. In patients with moderate renal impair-
ment, the incidence of renal-related adverse events resulting in
renal impairment induced by osmotic diuresis and volume
depletion was increased with dapagliflozin and canagliflozin
compared with the placebo. Regarding liver-related adverse
events, slight imbalances among patients treated with dapagli-
flozin or canagliflozin and control groups were probably not
associated with the study drug.
CLINICAL POTENTIAL OF SGLT2 INHIBITORS
The data from all of the clinical trials clearly show that SGLT2
inhibitors have the favorable effects of lowering blood glucose
levels as well as reducing bodyweight. The energy deficit result-
ing from excretion of calories into the urine induces weight loss
or has a weight-neutral effect. A follow-up study of these trials
showed the long-term efficacy and durability of these effects;
several SGLT2 inhibitors, such as dapagliflozin, are superior to
sulfonylureas in terms of changes in HbA1c and bodyweight
loss49. In addition to the blood glucose-lowering effect and the
reducing effect on bodyweight, SGLT2 inhibitors have a poten-
tial in amelioration of metabolic and cardiovascular risk factors,
blood pressure, lipid profile (HDL cholesterol), adiponectin,
and liver dysfunction induced by fatty liver.
SGLT2 inhibitors might also have a preventive effect on the
progression of diabetes by ameliorating b-cell dysfunction as
well as insulin resistance. Although improvement of b-cell func-
tion was found first in animal models67–73, there have been
some reports of improved b-cell function in clinical studies39,40.
These effects might be derived from indirect effects induced by
the attenuation of glucotoxity, as SGLT2 inhibitors do not
directly influence insulin secretion. SGLT2 inhibitors thus have
long durability of good glycemic control regardless of b-cell
conditions. In contrast to other current antidiabetic agents that
directly influence insulin secretion, inhibition of SGLT2 repre-
sents a particularly appealing approach to diabetes treatment
because of its novel mechanism of action. The mechanism of
action also suggests that SGLT2 inhibitors have the potential to
be used in combination with other oral antidiabetic agents as
well as insulin to exert additive or synergic effects on lowering
glucose levels in type 2 diabetes. In fact, clinical data on
combination therapy has shown favorable effects, with efficacy
in lowering HbA1c and reduction of bodyweight not inferior to
that in use in monotherapy.
The available data suggest a good tolerability profile. How-
ever, SGLT2 inhibitors have no experience of long clinical use.
Clinicians should carefully prescribe these drugs in light of
already reported and/or unexpected side-effects. In particular,
increasing risks of repeated urinary tract infections and genital
infections should be kept in mind. SGLT2 inhibitors might
cause hypovolemia as a result of their diuretic effect; the rele-
vant side-effects, such as stroke, should be of concern, especially
during a hot season. In patients with moderate renal impair-
ment, the use of dapagliflozin or high doses of canagliflozin
was associated with increased incidence of renal-related adverse
events. In addition, in lean, elderly patients, there might be a
risk for sarcopenia as a result of bodyweight loss. Furthermore,
a potential for an increase in hypoglycemia after combination
therapy, especially with sulfonylureas, has also been noted74–76.
CONCLUSION
Inhibition of the SGLT2 glucose transporter is a new therapeu-
tic approach for the treatment of type 2 diabetes. Clinical trials
of the SGLT2 inhibitors have shown therapeutic benefits in
attaining better glycemic control and reducing bodyweight in
type 2 diabetes patients. Some of these are now, or will soon
be, in clinical use. Although the available data suggest a good
tolerability profile, clinicians should carefully prescribe these
drugs in light of already reported and/or unexpected side-
effects. Further studies in large numbers and long-term clinical
use data are required to delineate efficacy and safety, and to
place these agents in the standard treatment of type 2 diabetes.
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